We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+27.07%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$39.1B
AUM Growth
+$5.57B
(+17%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-3.4%
Top 10 Holdings %
Top 10 Hldgs %
25.2%
Holding
834
New
111
Increased
262
Reduced
309
Closed
110
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$2.28B |
| 2 |
Otis Worldwide
OTIS
|
+$193M |
| 3 |
Burlington
BURL
|
+$191M |
| 4 |
AbbVie
ABBV
|
+$178M |
| 5 |
Wayfair
W
|
+$144M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$1.66B |
| 2 |
Lockheed Martin
LMT
|
+$339M |
| 3 |
Johnson & Johnson
JNJ
|
+$262M |
| 4 |
Pfizer
PFE
|
+$167M |
| 5 |
Target
TGT
|
+$141M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.52% |
| 2 | Healthcare | 19.78% |
| 3 | Consumer Discretionary | 13.09% |
| 4 | Financials | 11.33% |
| 5 | Industrials | 8.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
376
Moderna
MRNA
$22.5B
| $20.9M | 0.05% |
+325,000
| New | +$17.8M |
|
|
PRVL
377
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $20.8M | 0.05% |
1,396,169
+900,000
| +181% | +$13.9M |
|
378
Skyworks Solutions
SWKS
$10.1B
| $20.7M | 0.05% |
161,750
+58,900
| +57% | +$6.52M |
|
379
Teradyne
TER
$60.9B
| $20.5M | 0.05% |
+242,724
| New | +$16.3M |
|
380
Theravance Biopharma
TBPH
$876M
| $20.5M | 0.05% |
975,000
+200,000
| +26% | +$5.14M |
|
381
Tyson Foods
TSN
$20.5B
| $20.4M | 0.05% |
341,655
+5,100
| +2% | +$309K |
|
382
Diodes
DIOD
$3.93B
| $20.3M | 0.05% |
+400,000
| New | +$19.1M |
|
383
Akamai
AKAM
$17.8B
| $20.1M | 0.05% |
188,000
+3,200
| +2% | +$322K |
|
384
Ameren
AEE
$30.2B
| $20.1M | 0.05% |
+285,284
| New | +$20.7M |
|
385
Mid-America Apartment Communities
MAA
$15.7B
| $19.9M | 0.05% |
173,407
-40,143
| -19% | -$4.52M |
|
|
CVET
386
DELISTED
Covetrus, Inc. Common Stock
CVET
| $19.7M | 0.05% |
+1,100,000
| New | +$14.5M |
|
387
Lennar Class A
LEN
$21.2B
| $19.6M | 0.05% |
328,408
-5,372
| -2% | -$274K |
|
388
Conagra Brands
CAG
$7.18B
| $19.4M | 0.05% |
551,345
+10,800
| +2% | +$360K |
|
389
West Pharmaceutical
WST
$24.7B
| $19.4M | 0.05% |
+85,257
| New | +$16.8M |
|
390
Copart
CPRT
$26.8B
| $19.2M | 0.05% |
924,000
-16,800
| -2% | -$337K |
|
|
K
391
DELISTED
Kellanova
K
| $19.2M | 0.05% |
309,102
+4,899
| +2% | +$296K |
|
392
CDW
CDW
$17.9B
| $19.1M | 0.05% |
164,800
+800
| +0.5% | +$86.7K |
|
393
Allstate
ALL
$68.1B
| $19.1M | 0.05% |
197,019
-284,268
| -59% | -$27.9M |
|
394
Weyerhaeuser
WY
$18.6B
| $18.9M | 0.05% |
842,900
+659,612
| +360% | +$13.3M |
|
395
Oshkosh
OSK
$9.43B
| $18.8M | 0.05% |
261,927
-335,330
| -56% | -$22.9M |
|
396
Natera
NTRA
$39.3B
| $18.7M | 0.05% |
+375,000
| New | +$15.1M |
|
397
Corning
GLW
$135B
| $18.6M | 0.05% |
718,321
+22,000
| +3% | +$499K |
|
398
Amalgamated Financial
AMAL
$1.5B
| $18.6M | 0.05% |
1,469,294
+144,419
| +11% | +$1.53M |
|
399
Tesla
TSLA
$1.27T
| $18.4M | 0.05% |
+256,140
| New | +$13.9M |
|
400
Amcor
AMCR
$22.1B
| $18.4M | 0.05% |
361,078
-5,660
| -2% | -$264K |
|
Similar funds
Adage Capital Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Adage Capital Partners held 834 positions worth $39.1B, up 17% from $33.5B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Adage Capital Partners withdrew a net $1.33B in Q2 2020, closing 110 positions and reducing 309 holdings. Its most notable exit was Allergan plc, an estimated $1.66B position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Adage Capital Partners opened a new position in Royalty Pharma worth $2.23B.
- Adage Capital Partners's largest Q2 2020 buy was Royalty Pharma: 46,015,330 shares worth $2.23B.
- Adage Capital Partners added most to Burlington in Q2 2020, an estimated $191M increase.
- Adage Capital Partners's biggest Q2 2020 reduction was Lockheed Martin, cutting an estimated $339M.
- Adage Capital Partners fully exited Allergan plc in Q2 2020, selling an estimated $1.66B.
- Adage Capital Partners's ten largest holdings make up 25% of its $39.1B portfolio in Q2 2020.
- Adage Capital Partners opened 111 new positions and closed 110 in Q2 2020.
- Adage Capital Partners's portfolio value rose 17% quarter-over-quarter to $39.1B.
Based on Adage Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.